A case of gastric cancer with rhabdoid features showing better prognosis through S-1/CDDP chemotherapy

Yoshiko Mori, Masahiko Kobayashi, Shinichi Ishihara, Kouichi Mizobuchi, Miki Kishi, Takeshi Kurosaki, Soichiro Miyake, Nobuyuki Watanabe, Keigo Kimura, Yasutaka Kokudo, Atsushi Muraoka, Akihiko Tatemoto, Takeshi Nagasaka, Makoto Tsumura

Research output: Contribution to journalArticlepeer-review


Although gastric cancers (GCs) with rhabdoid features are rare, they are known to show a poorer prognosis compared with conventional GCs. Indeed, more than half of reported GCs with rhabdoid features died within 6 months after receiving any kind of initial treatment. Obviously, no effective chemotherapy has been reported. In this study, we present a case of GC with rhabdoid features which showed a better response to a chemotherapy, S-1/CDDP, and lived for over 12 months after the initial chemotherapy. A 75-year-old man was seen in our hospital for epigastralgia. Detailed examinations revealed that he had GC at Stage IV. Consequently, he underwent S-1/CDDP treatment. This treatment produced a good response for 6 months, minimizing the size of the primary tumor and eradicating distant metastases. Re-growth of the primary tumor without uprising distant metastasis was confirmed 8 months after the initial S-1/CDDP treatment, and the patient went through a gastrectomy for curative care. After surgery, a precise pathological examination revealed that the primary tumor possessed a poorly differentiated adenocarcinoma that contained tumor cells with typical rhabdoid features. In the end, the patient died of liver metastasis 13 months after the initial S-1/CDDP chemotherapy.

Original languageEnglish
Pages (from-to)829-832
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Issue number5
Publication statusPublished - May 2012


  • Cisplatin
  • Malignant rhabdoid tumor of stomach
  • S-1

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'A case of gastric cancer with rhabdoid features showing better prognosis through S-1/CDDP chemotherapy'. Together they form a unique fingerprint.

Cite this